Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers
Ente erogante: Commissione Europea - Horizon Europe
Scadenza
21 settembre 2027
522 giorni rimanenti
Forma
Fondo perduto
Budget totale
Non specificato
Contributo max
Non specificato
Descrizione del bando
Expected Outcome:Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes:Patients afflicted by lung, bowel, breast or prostate cancer[1], will benefit from the outcomes of evidence-based, tailored, innovative, affordable and accessible diagnosis- and treatment-centred clinical research programmes by comprehensive cancer infrastructures[2].Researchers, physicians, patient representatives, civil society, charities, foundations, insurance companies, SMEs and innovators[3] will seize opportunities to respectively co-create, support, upscale or commercialise outcomes of evidence-based, tailored, affordable and accessible clinical research programmes for the diagnosis and treatment of patients afflicted by lung, bowel, breast or prostate cancer.National and regional healthcare providers, healthcare payers, policymakers and authorities in European regions, EU Member States and Associated Countries have the evidence to engage in piloting, upscaling or implementing appropriate clinical research programmes for the diagnosis and treatment of patients afflicted by lung, bowel, breast or prostate cancer. Scope:Lung, bowel, breast and prostate cancer incidence, mortality and prevalence across EU Member States and Associated Countries are increasing while showing substantial variation, with Central and Eastern European communities, regions and countries particularly affected[4]. At the same time, the level of development of comprehensive cancer infrastructures continues to vary considerably across EU Member States and Associated Countries, contributing to inequalities, in particular in terms of clinical research capacity as well as quality of and access to innovative diagnostic and therapeutic interventions.Applicants should address all of the following:Comprehensive cancer infrastructures across the EU Member States and Associated Countries come together to conduct clinical research
Non capisci questo bando?
L'AI di Bandiora te lo spiega in modo semplice: requisiti, importi, scadenze e a chi è rivolto, tutto chiaro.
Registrati e fatti spiegare il bando dall'AIArea geografica
Tematiche
Requisiti dettagliati
Questo bando è rivolto a 3 tipologie di impresa in 4 settori ATECO nell'area eu.
Scopri con l'AI se questo bando è adatto alla tua azienda
Analisi automatica di compatibilità, requisiti e matching in tempo reale
Prova gratis 7 giorniQuesto bando fa per la tua azienda?
L'AI di Bandiora analizza la compatibilità con la tua azienda in tempo reale e ti assiste nella compilazione della candidatura, passo dopo passo.
Altri bandi che potrebbero interessarti
Support to test EIC innovations for public and private procurers
Commissione Europea
Scadenza: 17 aprile 2026
Accelerating the discovery and development of chemicals and innovative advanced materials through digitalisation and artificial intelligence (IA) (Innovative Advanced Materials for the EU partnership)
Commissione Europea - Horizon Europe
Scadenza: 21 aprile 2026
Improving availability of secondary raw materials through recycling (IA)
Commissione Europea - Horizon Europe
Scadenza: 21 aprile 2026
Monitoring of secondary raw materials (CSA)
Commissione Europea - Horizon Europe
Scadenza: 21 aprile 2026